RELATED: Wegovy results: First month and beyond Cardiovascular benefits In early 2024, the FDA expanded Wegovys approval for weight management, acknowledging that it can also be used to reduce the risk of cardiovascular death, heart attack, and stroke in adults with obesity or who are overweight and have existing heart disease
SURPASS-1 (Monotherapy) In the SURPASS-1 trial, Tirzepatide was evaluated as a monotherapy in 478 adults with T2D inadequately controlled with diet and exercise alone
Members access detailed protocol databases , stacking guides , and personalized recommendations based on thousands of documented research outcomes
Serious adverse events are rare in anecdotal reports, but anecdotal data cannot substitute for controlled trials
Retatrutide is a triple agonist (GLP-1/GIP/glucagon)
Residual alcohol on the skin can cause stinging when the needle penetrates